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Background: An altered intestinal mucosal barrier has been demonstrated in subsets of patients with IBS and FAP
and may be an additional biological factor contributing to symptom generation in children with FD. The objective
of this study was to determine if intestinal permeability is increased in children/adolescents with functional
dyspepsia (FD) and whether intestinal permeability is correlated with mucosal inflammation and/or symptoms of
anxiety or depression in this population.
Methods: A sugar absorption test was performed in 19 patients with FD and 19 controls. Anxiety and depression
were assessed in both groups utilizing a standard questionnaire. In FD patients, duodenal mean and peak mast cell
and eosinophil densities were determined.
Results: Intestinal permeability as measured by the sugar absorption test did not differ between children with FD
and controls. In children with FD, there was no correlation between permeability and mast cell density, eosinophil
density, anxiety scores, or depression scores, respectively.
Conclusions: Pediatric FD does not appear to be associated with increased small bowel intestinal permeability,
however, there are some limitations to the current study.
Trial registration: ClinicalTrials.gov; NCT00363597.
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Recurrent abdominal pain is a common complaint among
school-age children, being present in 13 to 17% at any
given time [1]. It represents the most common chronic
pain entity in pediatric patients. The great majority of
these patients can be diagnosed with a functional gastro-
intestinal disorder (FGID) [2,3]. As established by Rome
III, there are four FGIDs related to abdominal pain in chil-
dren including irritable bowel syndrome (IBS), functional
dyspepsia (FD), abdominal migraines, and functional ab-
dominal pain (FAP) [4]. FD is defined as upper abdominal
pain or discomfort unrelieved by defecation and in the
absence of a structural or biochemical explanation for the
pain [4]. FD, alone or in combination with irritable bowel
syndrome, is present in 45-87% of children/adolescents* Correspondence: cfriesen@cmh.edu
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reproduction in any medium, provided the orreferred to pediatric gastroenterologists for evaluation of
chronic abdominal pain [1-3].
An altered intestinal mucosal barrier has been demon-
strated in subsets of patients with IBS and FAP and may
be an additional biological factor contributing to symp-
tom generation in children with FD [5-7]. Barrier dys-
function results from alteration of the tight junctions
between epithelial cells which normally control the pas-
sage through the paracellular space. Barrier dysfunction
allows greater antigenic exposure and can facilitate mu-
cosal inflammation. To our knowledge, intestinal perme-
ability associated with barrier dysfunction has not been
previously evaluated in patients with FD. However, bar-
rier dysfunction can result from several factors which
may be relevant to FGIDs, including FD, such as chronic
stress, bacterial antigens, intestinal anaphylaxis, mast cell
activation and cytokines related to allergic or T helper 2
(TH2) responses [5]. Intestinal barrier dysfunction has
been demonstrated in children with food allergy even
when asymptomatic on a food elimination diet [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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intestinal permeability in a pediatric population diagnosed
with FD. The specific aims of this study were as follows:
1) to compare small bowel permeability between children
with FD and healthy children; 2) to explore the relation-
ship between intestinal permeability and mucosal eosino-
phil and mast cell densities, respectively, in children with
FD; and, 3) to explore relationships between intestinal per-
meability and anxiety and depression scores, respectively,
for children with FD and healthy children. Understanding
these relationships would help clarify the role of intestinal
permeability in symptom generation in FD, as well as
provide information on potential additional targets for
treatment in this population.
Methods
Participants
Patients were candidates for inclusion in this study if they
had been diagnosed with functional dyspepsia who were
aged 8–17 years (inclusive), had a demonstrated a lack of
clinic response to acid-reduction therapy, and were under-
going endoscopy to evaluate FD. Patients were excluded
from the study if any of the following criteria were
present: 1) previous abdominal surgery; 2) any chronic
non-gastrointestinal illness requiring regular medical care
(e.g., diabetes mellitus, juvenile rheumatoid arthritis, cystic
fibrosis, cancer); 3) any history of an adverse reaction to
lactulose or mannitol; 4) any use of aspirin within one
week prior to the study; 5) any use of antacids or laxatives
within 1 week prior to the study; 6) any use of steroids,
antihistamines or antihistamine-like drugs within 4 weeks
prior to the study; 7) any use of antibiotics within 4 weeks
prior to the study; 8) pregnancy; or, 9) non-English speak-
ing. Fifty-five patients were approached and 22 patients
agreed to participate in the study, yielding a 40% recruit-
ment rate. Three patients who participated in the study
demonstrated pathology on biopsy and were excluded
from data analysis, leaving 19 participants in the patient
group (13 females, 6 males; mean age = 13 ± 2.5 years). Of
these, one patient also was found to have eosinophilic
esophagitis on biopsy, but was retained in the study as this
was not an exclusion criterion.
For the control group, all respondents aged 8–17 years
(inclusive) were candidates for inclusion in the study. In
addition to the exclusion criteria noted above, control par-
ticipants were not admitted to the study if there was any
history of gastrointestinal symptoms (including abdom-
inal pain or discomfort, nausea, vomiting, bloating, diar-
rhea, or constipation) within the previous six months.
Twenty-four potential control participants responded to
the study advertisement. Twenty-one of the respondents
met eligibility criteria. Of these, two refused, leaving 19
controls enrolled in the study (10 females, 9 males; mean
age = 13 ± 2.6).Measures
Intestinal permeability
Intestinal permeability is measured by evaluating absorp-
tion of macromolecules which are not typically absorbed
across intestinal cells, but may pass through the paracellular
space when tight junction disruption is present [5]. Lactu-
lose is a non-digestible sugar and is absorbed through the
paracellular space following damage to the tight junction; it
is then rapidly metabolized by colonic bacteria upon entry
into the colon.As such, lactulose often is utilized to test
intestinal permeability as part of a Sugar Absorption Test
(SAT) [5]. Mannitol is a monosaccharide that is readily
absorbed through the transcellular pathway and is used to
control for mucosal (e.g. intestinal surface area) and non-
mucosal (e.g. gastric empting, intestinal transit, and im-
paired renal function) factors which may affect lactulose
absorption and metabolism. Sucrose is added to make a
hyperosmolar solution which has been shown to also im-
prove sensitivity of the test. In the SAT procedure, urine is
collected for 5 hours following administration of an oral
lactulose/mannitol/sucrose solution. The concentration of
lactulose and mannitol in the urine is determined and re-
sults are expressed as the ratio of lactulose to mannitol. An
increased ratio indicates increased paracellular permeability
due to tight junction dysfunction.
Urinary excretion of lactulose and mannitol was deter-
mined in the Toxicology Laboratory, CMH, KC, MO 64108
using an enzymatic method (available from INstruchemie,
AC Delfzijl, The Netherlands) adapted to the V-Twin auto-
mated chemistry analyzer. Recovery of the sugar probes
were expressed both quantitatively and as the lactulose/
mannitol ratio. A urine creatinine was determined in
order to express quantitative results in mmol/mol creatin-
ine. Urine creatinine was performed in the Toxicology
Laboratory, Children’s Mercy Hospital using the V-Twin
automated chemistry analyzer.
Gastrointestinal eosinophils and mast cells
Eosinophil density was determined from the routine
histology slides (hematoxylin and eosin stain) by count-
ing eosinophils beginning in what appeared to be the
most involved area after scanning the entire specimen.
Five consecutive fields (400× magnification) were evalu-
ated. Peak count was defined as the highest count of the
five fields, while mean count was defined as the average
of the five fields.
Mast cell density was evaluated utilizing immunohisto-
chemical techniques. Serial 3-μm paraffin sections were
air dried and heat fixed on slides. The sections were
deparaffinized with xylene and iodine and rehydrated in
a graded series of alcohol. Sections were stained on an
automated Dako Autostainer 3400 using Dako’s LSAB +
kit with streptoavidin conjugated to horseradish peroxid-
ase. The antibody utilized was tryptase monoclonal mouse
Neilan et al. BMC Research Notes 2014, 7:275 Page 3 of 5
http://www.biomedcentral.com/1756-0500/7/275antihuman mast cell tryptase, clone AA1, Dako. Mast cell
density was determined by counting mast cells beginning
in what appeared to be the most involved area after scan-
ning the entire specimen. Five consecutive fields (400×
magnification) were evaluated. Peak count was defined as
the highest count of the five fields, while mean count
defined as the average of the five fields.
Anxiety and depression
Symptoms of anxiety and depression were assessed using
the Behavioral Assessment System for Children (BASC)
[9]. The BASC is a paper-and-pencil questionnaire asses-
sing psychosocial functioning in youth with different
versions available for children (ages 8–11 years), adoles-
cents (ages 12–18 years), and parents (different versions
for parents of children 6–11 years and 12–18 years). The
BASC has demonstrated criterion-related and construct
validity, has good internal consistency for most individ-
ual subscales, and is widely used in both clinical and
research settings [9]. Standardized T scores for anxiety
and depression were used for the present study.
Procedures
This pilot study was a single-site, case-controlled, single-
blind observational design. Participants for the patient
group were recruited in a single hospital-based clinic
specializing in the evaluation and treatment of children
with chronic or recurrent abdominal pain. Participants
for the control group were recruited by advertisement at
the same hospital. Informed parental permission and
participant assent were obtained prior to the initiation of
any study procedures.
The study involved one visit to the hospital-based gastro-
enterology clinic. After providing informed parental per-
mission and participant assent, all participants completed
the Behavior Assessment System for Children (BASC)
and then underwent a differential sugar absorption test
(SAT) using lactulose/mannitol/sucrose solution to evalu-
ate intestinal permeability. Participants emptied their
bladders immediately prior to the start of the SAT and
then ingested 2 mL/kg (maximum 100 ml) of the sugar
solution. The SAT solution contained 5 grams lactulose,
2 grams mannitol and 40 grams sucrose dissolved in
demineralized water for a total volume of 100 mL. Partici-
pants did not eat or drink for 2 hours following ingestion
of the sugar solution. After 2 hours, participants could
consume any fructose-free foods and were asked to con-
sume at least 1 cup of water hourly. Urine was collected
for 5 hours following administration of the lactulose/
mannitol solution. Finally, for participants in the pa-
tient group only, an endoscopy with biopsy was per-
formed on a separate day as part of standard care and a
minimum of 4 mucosal biopsies were obtained from
the duodenum for later evaluation.All study personnel performing procedures and asses-
sing outcomes were blinded to group assignment. The
study protocol was approved by the Children’s Mercy
Kansas City Institutional Review Board.
Sample size
A priori analysis provided a sample size estimate of 18
per group which would allow 80% power to detect a dif-
ference for mean permeability between 0.015 and 0.045
assuming a standard deviation of 0.03.
Statistical analysis
Independent-sample t- tests (2-tailed) were used to
evaluate mean differences in the lactulose/mannitol ratio
in the patient group compared to the control group. In
the FD patients, Pearson correlation coefficients were
calculated and used to evaluate associations between the
lactulose/mannitol ratio and mast cell and eosinophil
densities, as well as the BASC anxiety and depression
subscale scores, respectively.
SPSS 18.0 for Windows computer program, SPSS Inc.
Chicago, IL was used to complete the analyses. All ana-
lyses used a set significance limit of α = 0.05.
Results
Intestinal permeability in FD versus controls
Mean values for the lactulose/mannitol ratio (L/M) did
not differ between FD patients and controls (0.034 ± .01
vs. 0.032 ± .01, p = .141). Only one FD patient had a L/M
ratio exceeding the mean plus two standard deviations
for the control subjects.
Intestinal permeability in relation to mast cell and
eosinophil densities
Mean mast cell density ranged from 7.2 to 27.6 cells/hpf
(mean 16.0) and peak mast cell density ranged from 8 to
34 cells/hpf (mean 22.0). Mean eosinophils ranged from
7.2 to 54.2 cells/hpf (mean 24.6) and peak eosinophils
ranged from 12 to 76/hpf (mean 38.8). There were no
significant correlations between L/M and mast cell or
eosinophil densities.
Intestinal permeability in relation to anxiety and
depression
Mean values for anxiety differed significantly between
FD patients and controls for parent-report (55.8 ± 11.0
vs. 46.4 ± 10.0, p = .01), but not for self-report (51.2 ±
11.2 vs. 44.7 ± 9.2, p = .06). Mean values for depression
also differed significantly between FD patients and con-
trols for parent-report (51.4 ± 9.5 vs. 44.7 ± 9.0, p = .03),
but not for self-report (47.1 ± 5.7 vs. 44.6 ± 2.5, p = .09).
There were no significant correlations between L/M and
scores on the anxiety or depression subscales based on
parent- or self-report.
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In the current study, FD does not appear to be associ-
ated with abnormal small bowel permeability. This
stands in contrast to previous findings supporting alter-
ation in the intestinal mucosal barrier in IBS and FAP.
This suggests that either FD is not associated with altered
permeability or perhaps, if there is a permeability abnor-
mality, the anatomic sight is different from these other
FGIDs. This latter explanation remains a possibility given
that anatomic differences have been noted between FD
and IBS with regards to location for inflammation, dysmo-
tility, and visceral sensitivity.
The intestinal barrier is highly regulated by immune
factors and increased permeability has been seen in
other conditions associated with inflammation, such as
Crohn’s disease and Celiac disease [10-13]. Mucosal eo-
sinophilia has been implicated as a potentially significant
factor in FD. Talley and colleagues found that FD in
adults is associated with a significant increase in duo-
denal eosinophils as compared to controls [14]. Consist-
ent with this, our own research group found duodenal
mucosal eosinophilia (defined as a peak count of ≥20
eos/hpf ) in 79% of children undergoing endoscopy with
mucosal biopsy for evaluation of FD [15]. FD also has
been associated with a significant increase in antral mast
cells in adults [16]. Importantly, barrier dysfunction is
associated with increased IL-4 and decreased IFN-δ
expression in the gut mucosa (consistent with a TH2
response) [17]. Thus, the potential relationship between
intestinal permeability and inflammation, as defined by
mast cell and eosinophil densities, also was explored.
However, no relationship was found, seeming to indicate
that altered permeability is not a mechanism by which
mast cells or eosinophils contribute to symptom gener-
ation in FD. However, it also is possible that the inflam-
mation in FD is limited to a short enough segment of
the proximal gastrointestinal tract that the L/M ratio,
influenced by permeability across the entire small bowel,
may not be a sensitive enough measure. There may be
value in future assessment of the relationship between
structural proteins related to permeability, such as zonu-
lin or occludin, and inflammatory cell density in the
proximal small bowel of FD patients.
Finally, there is an increasing body of evidence that
stress, both acute and chronic, affects intestinal barrier
function [18-20]. This pathway appears to be mediated
by the release of corticotropin releasing hormone with
subsequent activation of mucosal mast cells [19,21]. In
the current study, however, no correlation was found
between intestinal permeability and scores for anxiety or
depression, respectively. Alteration of the mucosal bar-
rier as indicated by the L/M ratio does not appear to
be the mechanism by which anxiety and depression
contribute to symptom generation in FD.Limitations
The sample size chosen for the current study was calcu-
lated to be able to detect a 3-fold difference in the L/M
ratio. It is possible that a lesser difference would be
physiologically relevant and that the sample size was too
small to detect such differences. Although we evaluated
for allergic inflammation (i.e. eosinophil and mast cell
density) in the FD patients, a deficiency in the current
study was that history regarding food allergy was not
obtained in either FD patients or controls. It is possible
that the effects of food allergy on permeability are inde-
pendent of eosinophil and mast cell density. Lastly, it is
possible that permeability abnormalities, if present in
FD, are more localized to the duodenum and therefore
not reflected by the sugar absorption test.
Conclusions
Increased small bowel permeability does not appear to be
a biomarker of FD in children even in the presence of ele-
vated mast cell density, eosinophil density, anxiety scores
or depression scores. However, given the limitations of the
current study, future studies will be needed with a larger
population, controlling for food allergy, and assessing
whether more focal barrier disruptions are present (e.g.
utilizing a Ussing chamber) before making any definitive
conclusion regarding a potential role for barrier dysfunc-
tion in the pathophysiology of FD.
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